Welcome to our dedicated page for Universe Pharmaceuticals SEC filings (Ticker: UPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Universe Pharmaceuticals INC SEC filings document the disclosures of a Cayman Islands foreign private issuer operating a pharmaceutical production and distribution business in China. Form 6-K reports cover interim financial results, revenue and cost categories for company and third-party products, and current reports tied to governance and capital-structure matters.
The filing record also includes proxy materials and annual general meeting results, an equity incentive plan, and amendments related to ordinary-share structure, including Class A and Class B ordinary shares and authorized share capital. These filings describe shareholder voting matters, board and compensation arrangements, share-based awards and formal corporate actions affecting UPC securities.
Universe Pharmaceuticals INC (UPC) has amended a prior Form 6-K to include the full notice and proxy statement for its annual general meeting of shareholders. The meeting is scheduled for September 30, 2026 at 10:00 a.m. Beijing Time in Ji’an, Jiangxi, China, with a record date of August 31, 2026.
Shareholders will vote on eight proposals: re-election of five directors; a conditional 1-for-10 share consolidation of all Class A and Class B ordinary shares (effective on the 25th trading day after any 12‑month “Trigger Event” when the Nasdaq closing bid is below $1.00 for three consecutive trading days); adoption of an amended and restated memorandum of association to reflect the consolidation; and a proposal allowing adjournment of the meeting if more time is needed to secure votes. Each Class A share carries one vote, and each Class B share carries 100 votes, with 5,008,313 Class A and 16,077 Class B shares outstanding as of the record date. The board unanimously recommends voting “FOR” all proposals.
Universe Pharmaceuticals INC (UPC) reports that Star Voyage International Limited and its owner, Xuncheng Chen, together beneficially own 497,917 Class A ordinary shares, representing 9.94% of the Class A shares. This percentage is based on 5,008,313 Class A ordinary shares outstanding as of July 27, 2026. All reported voting and dispositive powers over these 497,917 shares are shared, with no sole voting or dispositive power reported for either Star Voyage International Limited or Xuncheng Chen.
Universe Pharmaceuticals INC (UPC) received a Schedule 13G reporting that August Luck Global Limited and Xuefeng Li together beneficially own 465,258 Class A ordinary shares. This represents 9.29% of the Class A ordinary shares, based on 5,008,313 shares outstanding as of July 27, 2026.
The 465,258 shares are held by August Luck Global Limited, a British Virgin Islands company that is wholly owned and controlled by Xuefeng Li of the People’s Republic of China. Both reporting persons disclose shared voting and dispositive power over these shares, with no sole voting or dispositive power.
Universe Pharmaceuticals INC (UPC) received a Schedule 13G reporting that Meridian Prosperous Limited and its sole owner, Shanshan Lu, beneficially own 498,922 Class A ordinary shares, representing 9.96% of the Class A shares outstanding. The shares are held by Meridian Prosperous Limited, with voting and dispositive power shared between the entity and Lu.
The reported ownership percentage is based on 5,008,313 Class A ordinary shares outstanding as of July 30, 2026. Meridian Prosperous Limited is organized in the British Virgin Islands, and Lu is a citizen of the People’s Republic of China.
Universe Pharmaceuticals INC (UPC) received a Schedule 13G reporting that Horizon Ridge Limited and its sole owner, Shan Xie, beneficially own 499,424 Class A ordinary shares. This represents 9.97% of the Class A ordinary shares, based on 5,008,313 shares outstanding as of July 27, 2026.
Both Horizon Ridge Limited and Shan Xie report shared voting and dispositive power over 499,424 shares and no sole voting or dispositive power. The filing reflects passive beneficial ownership, with a joint filing agreement attached as an exhibit.
Universe Pharmaceuticals INC (UPC) has a significant shareholder disclosure on Schedule 13G. Origin Force Intelligence Limited and its sole owner, Piao Ye, report beneficial ownership of 916,759 Class A ordinary shares, representing 18.30% of the Class A shares.
All voting and dispositive power over these 916,759 shares is reported as shared, with no sole voting or dispositive power. The percentage is calculated based on 5,008,313 Class A ordinary shares outstanding as of July 27, 2026.
Universe Pharmaceuticals INC (UPC) received a Schedule 13G reporting passive beneficial ownership of its Class A ordinary shares by Clever Way Global Limited and Lu Yang. The filing states that Clever Way Global Limited beneficially owns 498,922 Class A ordinary shares, all of which are also attributed to Lu Yang through ownership and control of Clever Way Global Limited. This position represents 9.96% of the Class A ordinary shares, based on 5,008,313 shares outstanding as of July 27, 2026. Voting and dispositive power over these shares is reported as shared, with no sole voting or dispositive power for either reporting person.
Universe Pharmaceuticals INC (UPC) received a Schedule 13G indicating that Orbis BioCapital Limited and Chunhua Zheng collectively report beneficial ownership of 499,926 Class A ordinary shares. This represents 9.98% of the Class A ordinary shares outstanding, based on 5,008,313 shares outstanding as of July 27, 2026.
Both Orbis BioCapital Limited, a British Virgin Islands company, and Chunhua Zheng, an individual resident in China, report shared voting and dispositive power over these 499,926 shares and no sole voting or dispositive power. Orbis BioCapital Limited is wholly owned and controlled by Chunhua Zheng.
Universe Pharmaceuticals INC (UPC) received a Schedule 13G reporting passive ownership of its Class A ordinary shares by Whitmore Limited and Chengming Tang. Whitmore Limited, a British Virgin Islands company wholly owned and controlled by Chengming Tang, reports beneficial ownership of 499,424 Class A ordinary shares.
This position represents 9.97% of the Class A ordinary shares, based on 5,008,313 shares outstanding as of July 27, 2026. Both Whitmore Limited and Chengming Tang report shared voting and dispositive power over these 499,424 shares and no sole voting or dispositive power.
Universe Pharmaceuticals INC (UPC) has called its 2026 annual general meeting of shareholders for September 30, 2026 at 10:00 a.m. Beijing Time in Jiangxi, China. Holders of Class A and Class B ordinary shares as of the August 31, 2026 record date may vote in person or by proxy.
Shareholders are asked to re-elect five current directors and approve a conditional 1‑for‑10 Share Consolidation of both Class A and Class B ordinary shares, which would take effect only if a defined trading-price Trigger Event occurs. In connection with this, authorized capital would change from 1,800,000,000 Class A and 200,000,000 Class B shares at US$0.00001 par value to 180,000,000 Class A and 20,000,000 Class B shares at US$0.0001 par value, with fractional entitlements rounded up.
As of the record date, 5,008,313 Class A ordinary shares and 16,077 Class B ordinary shares were issued and outstanding, with one vote per Class A share and one hundred votes per Class B share. The board unanimously recommends voting in favor of all proposals, including adoption of an amended and restated memorandum of association to reflect any approved Share Consolidation and authority to adjourn the meeting if additional proxy solicitation is needed.